November 14 - 17, 2026 | Washington, DC
We’re looking forward to attending ObesityWeek 2026 and connecting with researchers advancing obesity and metabolic disease therapeutics. Meet with our team to explore translational preclinical models and study strategies for obesity and related cardiometabolic diseases.
Taconic will also present new research highlighting GLP-1 therapeutics, diet-induced obesity, and the impact of obesity on cancer therapeutic response.
Taconic offers established and next-generation models to support obesity and metabolic research, from evaluating weight loss and metabolic endpoints to investigating emerging therapeutic targets.
A widely used model of diet-induced obesity and metabolic dysfunction for evaluating therapeutic effects on body weight, glucose homeostasis, insulin sensitivity, and related metabolic endpoints.
A genetically humanized GLP-1 receptor model designed to support in vivo evaluation of therapeutics targeting human GLP-1R, including next-generation incretin therapies.
A translational obesity model for evaluating body weight, adiposity, glucose metabolism, and pharmacologic responses in a larger rodent species.
Taconic Biosciences will present three scientific posters at ObesityWeek 2026 exploring translational approaches to obesity therapeutics, metabolic outcomes, and obesity-associated cancer research.
Saturday, November 14, 2026 | 7:30pm - 8:30pm EST
Session: Energy Expenditure, Metabolic Rate & Adaptation
Poster Title: Humanized GLP-1R Mice Enable Translational Evaluation of Orforglipron With Reduced Energy Intake and Improved Glucose Tolerance
Author: Laura Griffin, PhD
Presented by Taconic Biosciences
Saturday, November 14, 2026 | 7:30pm - 8:30pm EST
Session: Energy Expenditure, Metabolic Rate & Adaptation
Poster Title: Cagrilintide Reduces Body Weight and Prevents Adiposity Gain in Diet-Induced Obese Rats
Author: Laura Griffin, PhD
Presented by Taconic Biosciences
Monday, November 16, 2026 | 2:30pm - 3:30pm EST
Session: Obesity, Cancer Risk & Cancer-Related Outcomes
Poster Title: Obesity Alters Anti-PD-1 Tumor Response and Metabolic Signatures in a Syngeneic Colon Mouse Model
Author: Laura Griffin, PhD
Presented by Taconic Biosciences
Our team brings extensive expertise in managing animal models across diverse research areas. By sharing practical insights into model selection, colony management, and welfare-focused strategies, we aim to help researchers design studies that are both efficient and responsible.
Associate Director, Cardiometabolic Portfolio
Laura Griffin, PhD, is the Associate Director of the Cardiometabolic Disease Portfolio at Taconic Biosciences, where she leads strategy and scientific positioning for models and services supporting CVMD research. She works closely with pharmaceutical and biotech researchers to design translational preclinical approaches that integrate genetic models, diet conditioning, and study design. Dr. Griffin has over a decade of experience in preclinical research and model application, with expertise in disease modeling and experimental strategy. She has contributed to the development and positioning of key cardiometabolic platforms, including diet-induced obesity systems and humanized receptor models. Her work focuses on helping researchers build study-ready systems that improve reproducibility and better reflect human disease.
Senior Director, Neurobiology and Rare Disease Portfolio
Dr. Sarah Sterlace joined Taconic in 2024 and is currently Director of Portfolio Management focusing on Neurobiology and Rare Disease. Sarah has more than 10 years of experience in drug discovery and life sciences support with an emphasis in emerging technologies and customer-focused solutions for advancing translational research.
